Efficacy and safety of low-dose valganci
โ
Jeong M. Park; Kathleen D. Lake; Juan D. Arenas; Robert J. Fontana
๐
Article
๐
2005
๐
John Wiley and Sons
๐
English
โ 85 KB
๐ 1 views
The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days) and standard oral ganciclovir (1 g three times a d